Genetic Markers Found To Predict Individuals At Risk For Serious Drug Induced Liver Injury
ScienceDaily (May 31, 2009) — The International Serious Adverse Events Consortium (SAEC) has announced initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI).
A fact which has influenced the drugs that a doctor can prescribe to patients is the different responses and possible adverse effects that each patient has to the medicine. The International Serious Adverse Events Consortium (SAEC) has formed a hypothesis that many of these differences are genetically based. Its research studies are exploring the impact genetics can have on how individuals respond to medicines. There are a large number of drugs that can cause injuries to the liver and in rare cases this can lead to acute liver failure. Research suggests that Drug Induced Liver Injury (DILI) is of a genetic contribution. In a Nature Genetics paper published on May 31, the SAEC and Newcastle University's analysis of a subset of DNA patients has led to the discovery that the allele HLA-B*5701 is a major determinant of whether patients will fall victim to liver injury induced by flucloxacillin, an antibiotic widely used in Europe and Australia for the treatment of staphylococcal infections.
HLA-B is one of a number of highly variable genes that are responsible for immune function. The study found that individuals carrying at least one copy of HLA-B*5701 were 80-100 times more likely than non-carriers to develop DILI in response to this antibiotic. In addition to HLA-B*5701, variations on chromosome 3 were also found to influence the risk for DILI. These findings provide an initial insight into the mechanisms of DILI and may lead to the ability to identify individuals who have an increased risk of flucloxacillin related liver injury. Despite this increased risk than non-carriers, only a small proportion of carriers actually develop liver problems in response to flucloxacillin. Further analysis is therefore needed to determine whether a clinically useful biomarker test could be developed for this susceptibility.
References:
International Serious Adverse Events Consortium (2009, May 31). Genetic Markers Found To Predict Individuals At Risk For Serious Drug Induced Liver Injury. ScienceDaily. Retrieved June 2, 2009, from http://www.sciencedaily.com /releases/2009/05/090531141333.htm
Picture – http://www.health.msn.com/
ScienceDaily (May 31, 2009) — The International Serious Adverse Events Consortium (SAEC) has announced initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI).
A fact which has influenced the drugs that a doctor can prescribe to patients is the different responses and possible adverse effects that each patient has to the medicine. The International Serious Adverse Events Consortium (SAEC) has formed a hypothesis that many of these differences are genetically based. Its research studies are exploring the impact genetics can have on how individuals respond to medicines. There are a large number of drugs that can cause injuries to the liver and in rare cases this can lead to acute liver failure. Research suggests that Drug Induced Liver Injury (DILI) is of a genetic contribution. In a Nature Genetics paper published on May 31, the SAEC and Newcastle University's analysis of a subset of DNA patients has led to the discovery that the allele HLA-B*5701 is a major determinant of whether patients will fall victim to liver injury induced by flucloxacillin, an antibiotic widely used in Europe and Australia for the treatment of staphylococcal infections.
HLA-B is one of a number of highly variable genes that are responsible for immune function. The study found that individuals carrying at least one copy of HLA-B*5701 were 80-100 times more likely than non-carriers to develop DILI in response to this antibiotic. In addition to HLA-B*5701, variations on chromosome 3 were also found to influence the risk for DILI. These findings provide an initial insight into the mechanisms of DILI and may lead to the ability to identify individuals who have an increased risk of flucloxacillin related liver injury. Despite this increased risk than non-carriers, only a small proportion of carriers actually develop liver problems in response to flucloxacillin. Further analysis is therefore needed to determine whether a clinically useful biomarker test could be developed for this susceptibility.
References:
International Serious Adverse Events Consortium (2009, May 31). Genetic Markers Found To Predict Individuals At Risk For Serious Drug Induced Liver Injury. ScienceDaily. Retrieved June 2, 2009, from http://www.sciencedaily.com /releases/2009/05/090531141333.htm
Picture – http://www.health.msn.com/
No comments:
Post a Comment